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Small airways are affected in asthma, but gender differences have not been investigated.
This study aims to assess whether gender differences exist in the extent of small airway in-
volvement in asthma.
Sixteen patients with mild-to-moderate asthma (seven males, median (range) age 39 (19e
56) years, FEV1%predicted 89% (62e120), PC20 Methacholine (MCh) 0.4 mg/mL (0.1e4.2)) par-
ticipated in the study. MCh-induced air trapping at end-expiratory CT scans, alveolar and bron-
chial exhaled Nitric Oxide (eNO), Single-Breath N2 closing volume, FEF25e75%, FEF50% and %
change in FVC at PC20 adenosine-5
0-monophosphate (AMP) and at PC20MCh were evaluated.
Multiple regression analyses evaluated whether gender, body mass index and age were explan-
atory variables for the severity of air trapping.
Males had significantly larger MCh-induced increases in low attenuation areas on CT than fe-
males, 6% (1e9) versus 2% (1e7), pZ 0.012. Males had significantly more signs of MCh-in-
duced air trapping in the non-dependent lung lobes than females. Male gender was the sole
factor explaining higher values of MCh-induced signs of air trapping. Females had higher bron-
chial eNO values than males, 4 nL/s (2e7) versus 2 nL/s (1e4), pZ 0.04.
Small airway involvement in asthma as reflected by MCh-induced air trapping at CT was sig-
nificantly larger in males than females even in this relatively small group. Bronchial eNO, re-
flecting partially small airway inflammation, was higher in females than males. These data
suggest that the small airways are affected differently in males and females with asthma.
Males exhibit small airway involvement by attenuated small airway patency and females by
small airway inflammation.
ª 2008 Elsevier Ltd. All rights reserved.0) 503613532; fax: þ31 (0) 503619320.
cg.nl (J. Cohen).
8 Elsevier Ltd. All rights reserved.
Table 1 Study design
Visit 1 (day 1) Visit 2 (day 2) Visit 3 (day 9)
eNO AMP challenge eNO
SBN2 SBN2
MCh challenge CT scan: inspiration &
expiration
MCh challenge
CT scan: expiration e
post MCh
The measurements were performed in the order presented in
Table 1 from top to bottom. eNO: exhaled nitric oxide, SBN2:
single-breath nitrogen test, MCh: Methacholine, AMP: adeno-
sine-50-monophosphate.
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Asthma is a chronic disease that is characterized by
inflammation, obstruction and hyperresponsiveness of the
airways. Pathological and physiological evidence exists that
besides large airways, the small airways (i.e. airways with
an internal diameter< 2 mm) also contribute to the sever-
ity of asthma.1,2,3 Already in 1977 McFadden et al. demon-
strated that the small airways can be the predominant site
of flow limitation in asthma.4 In support of these early find-
ings, a more recent study demonstrated that the small air-
ways are largely responsible for the heterogeneity in
ventilation that is observed in asthma.5 It has been shown
that large airways and small airways contribute differently
to the physiological response to inhaled histamine.6 Cur-
rently, the best available tool to image specific individual
airways in vivo and to evaluate small airway disease is com-
puted tomography (CT).7 CT has been used functionally to
assess the small airway contribution to airway hyperrespon-
siveness in asthma.8
Asthma is more common in boys than girls during early
childhood. The prevalence equalizes between the genders
during adolescence and then switches to a female pre-
dominance in adulthood.9 Adult females portray more air-
way hyperresponsiveness than males,10 and prevalence of
severe asthma is also higher in females than males.11 A
role for sex hormones in the development and severity of
asthma seems likely,11 but differences in lung and airway
development both in utero and during maturation into
adulthood may also be partially responsible for the gender
differences in asthma prevalence.12 For instance, at birth
females have a higher ratio of large airways to small air-
ways than males,13 and it has been suggested that boys
have more respiratory bronchioles per lung volume than
girls.14 Furthermore, the growth of airways is slower than
the growth of lung parenchyma in boys, so-called dysynap-
tic growth, whereas in girls the growth of airways is propor-
tional to the growth of parenchyma.12 This dysynaptic
growth originates in early childhood, remains constant dur-
ing growth,15 and therefore may explain differences in level
of lung function parameters between both genders of iden-
tical height and age.12
Although it is evident that there are gender differences
in small airway development and patency in childhood, it is
still unclear whether such differences are still prominent in
adulthood. Furthermore, it is unknown whether the extent
to which small airway inflammation contributes to asthma
differs between males and females. The aim of the present
study was to investigate whether there are gender differ-
ences in parameters of small airway function and inflam-
mation in patients with mild-to-moderate asthma who
participated in a study investigating effects of a small-
particle ICS on small airway parameters.
Materials and methods
Study design
This study was part of a randomized trial to assess effects
of a small-particle inhaled corticosteroid on small airways
in asthma, and was registered in a public trial database(clinicaltrials.gov identifier NCT00163345). The current
study aims were evaluated in data obtained during the 2-
to 3-week baseline period of the trial. The three visits in
the baseline period are described in Table 1.
Subjects
Subjects were recruited from the outpatient clinic of the
Department of Pulmonology of the University Medical
Center Groningen and with advertisements in local papers.
The local Medical Ethics Committee reviewed and approved
the study protocol, and all subjects gave written informed
consent.
Subjects of either gender, between 18 and 60 years of
age, with a history of asthma according to GINA criteria,16
using short-acting b2-agonists as needed only, with a base-
line FEV1 60% of predicted reference value,17 bronchial
responsiveness to both Methacholine (MCh) and adeno-
sine-50-monophosphate (AMP) defined as a provocative con-
centration causing a 20% fall in FEV1 from baseline,
PC20MCh 4.9 mg/mL and PC20 AMP 40 mg/mL, and
proven atopy defined by at least one positive skin prick
test to 18 common aero-allergens were included in the
study.
Current smokers or ex-smokers who quit smoking< 1
year prior to study participation or with 10 packyears
were excluded. In addition subjects with (1) a history of
COPD or other pulmonary or concomitant diseases expected
to interfere with the study, (2) unstable asthma (defined as
more than three exacerbations in the past year or one ex-
acerbation in the past 2 months), (3) concomitant medica-
tion that was not allowed (e.g. oral corticosteroids within 4
weeks prior to study participation), (4) intolerance for
short-acting b2-agonists (SABA), and (5) pregnant or lactat-
ing females or females lacking an effective method of con-
traception were not eligible for the study.
Air trapping quantified with CT
An inspiratory CT scan was acquired during a 10-s breath-
hold at full inspiration, followed by a CT scan during a
10-s breathhold at end-expiration. Subsequently, a Metha-
choline provocation test was performed on site, followed
by an end-expiratory scan immediately after PC20MCh had
been reached.
1266 J. Cohen et al.In- and expiratory manoeuvres were practiced twice
before the procedure and subjects were coached by
a trained technician during scanning in the supine position.
All scans were low-dose scans, performed on a 16-slice
MultiDetector CT (MDCT) scanner (Siemens Somatom Sen-
sation 16, Siemens AG Medical Solutions, Erlangen, Ger-
many) at 120 kVp, 25 mAs (inspiration) and 30 mAs
(expiration), 0.5 second rotation time. A table feed of
18 mm per rotation, and a 1 mm slice thickness with
0.6 mm increment were used. The estimated effective radi-
ation dose was 0.78 mSv for inspiratory scans and 0.94 mSv
for expiratory scans.
Anonymized MDCT data were sent to MeVis (Center for
Medical Diagnostic Systems and Visualization, Bremen,
Germany) and analyzed by the advanced image analysis
software MeVisPULMO3D. A detailed description of the lung
segmentation with MeVisPULMO3D software is provided in
the online repository. Based on the segmentation, quanti-
tative volumetric and densitometric analyses were per-
formed of total lung, right and left lung, separately and of
each individual lung lobe. The parameters used in the
analysis were volume (mL), mean lung density (MLD; in
Hounsfield Units (HU)), 15th percentile density (PD15; HU),
and percentage of low attenuation areas (LAA; %). LAA
were defined at a cut-off point of 950 HU. Methacholine-
induced air trapping on CT was defined at baseline as the
absolute change in MLD, PD15 and LAA between the two ex-
piratory scans before and after Methacholine. The change
in volume between the two expiratory scans before and af-
ter Methacholine was also corrected for inspiratory lung
volume by using the following equation:Volume ChangeZ
ððInspiration ExpirationÞ  ðInspiration Expiration postMChÞÞ
ðInspiration ExpirationÞ  100%Lung areas were partitioned into the dependent lung
lobes and the non-dependent lung lobes. As the CT scan was
acquired in the supine position, the dependent lung lobes
consisted of the dorsally positioned lung lobes, i.e. the
right and left lower lobes. The non-dependent lung lobes
consisted of the upper lobes and middle lobe.
Alveolar and bronchial eNO
Endogenous Nitric Oxide production is increased in asthma
due to inflammation of airway epithelium.18 Measurement
of alveolar exhaled Nitric Oxide (eNO) reflects inflamma-
tion in alveoli and small airways,19 whereas bronchial eNO
flux is thought to reflect inflammation not only in larger air-
ways but also to some extent in smaller airways.20 An eNO
measurement was performed at multiple flow rates (30 mL/
s, 50 mL/s, 100 mL/s and 200 mL/s) on a NIOX (Aerocrine,
Stockholm, Sweden) at two baseline visits, 1 week apart.
The mean eNO value of three technically acceptable at-
tempts per flow rate was used for analysis. Alveolar eNO
fraction (ppb) as well as the bronchial NO flux (nL/s)
were calculated with a modification of the two-compart-
ment model of nitric oxide exchange by Tsoukias andGeorge.21 The eNO values measured on day 9 were used
in the analysis.
Closing volume with the single-breath N2 test
Closing volume measured with a Single-Breath Nitrogen
Test (SBN2) reflects air trapping due to small airways ob-
struction.22,23 An SBN2 test was performed (Quark PFT
,
Cosmed, Rome, Italy) at two visits, 1 week apart. Subjects
were coached into tidal breathing, after which they were
instructed to exhale to residual volume (RV), followed by
a slow inspiration of pure oxygen to total lung capacity.
Hereafter, they slowly exhaled to RV, during which N2 wash-
out was measured and plotted against lung volume. Calcu-
lation of closing volume and dN2 is described in the online
repository. The values measured on day 9 were used in
the analysis.
Lung function testing
Spirometry was measured with a daily-calibrated dry wedge
spirometer (Jaeger Masterscope, Hoechberg, Germany).
Additionally to the measurement of Forced Expiratory
Volume in 1 s (FEV1), Slow inspiratory Vital Capacity (SVC)
and Forced Vital Capacity (FVC) were measured in a com-
bined manoeuvre. Mean forced expiratory flow measured
between 25% and 75% of FVC (FEF25e75%) and mean flow
at 50% of FVC (FEF50%) were only available from measure-
ments on day 1.
Methacholine and AMP challenge testing was performed
using the standardized 2-min tidal breathing protocol.24 Inaddition to the FEV1 measurement at 30 and 90 seconds af-
ter each inhaled dose of either Methacholine or AMP, both
FVC and SVC were measured. Subjects received doubling
doses of Methacholine bromide (0.038e19.6 mg/mL) at
two visits, 1 week apart, and doubling doses of AMP
(0.04e320 mg/mL) at one visit on day 2. PC20, the provoca-
tive concentration of either Methacholine or AMP causing
a 20% fall in FEV1, was calculated using logelinear interpo-
lation. The fall in FVC and SVC from baseline (DFVC% and
DSVC%) at PC20, which is considered to reflect small airways
closure during bronchoprovocation, was calculated using
logelinear interpolation.25,26
Analysis
Data are expressed as medians (ranges). ManneWhitney U
tests were used to assess gender differences (SPSS 12.0.2.
for Windows, SPSS INC. Chicago, IL, USA). Wilcoxon signed
ranks tests were used to assess differences in MCh-induced
air trapping in dependent versus non-dependent lung lobes.
A multivariate regression analysis was performed to assess
whether age, gender and body mass index (BMI) were inde-
pendent predictive factors of air trapping.
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Sixteen subjects (seven males, nine females) using short-
acting b2-agonists as needed only participated in the study.
Demographics, lung function and CT scan data are pre-
sented in Table 2.
Bronchial eNO was significantly higher in females than in
males, median (range) 3.9 nL/s (1.6e7.4) versus 2.0 nL/s
(1.0e3.7), respectively (pZ 0.04), as was the absolute
lung volume on expiratory CT scan at baseline (Table 2,
Fig. 1). There was no statistically significant gender differ-
ence with respect to age, body mass index, airway hyper-
responsiveness, closing volume, dN2, spirometry, and
other parameters of CT scan at baseline. Nevertheless,
closing volume and dN2 were larger and FEF25e75% and
FEF50% were lower in males than in females (Fig. 2aed),
which is compatible with increased small airway involve-
ment in males.
Table 3 presents measures of MCh-induced air trapping
quantified with CT. Median (range) MCh-induced increase in
end-expiratory lung volume is larger in males than in fe-
males, 25%9e35 versus 14%2e39 respectively, though this did
not reach statistical significance (pZ 0.091; Table 3,
Fig. 3a). MCh-induced changes in MLD were also larger in
males than in females (Table 3) with borderline significance
(pZ 0.055). MCh-induced changes in LAA were significantly
larger in males than in females (pZ 0.016). MCh-induced
air trapping in the non-dependent lobes (ventral lung lobes,
i.e. right and left upper lobes and middle lobe) was signifi-
cantly larger inmales than in females (Table 3, Fig. 3b and c).
A multivariate regression analysis demonstrated that
gender was the only factor that significantly influences the
level of MLD, PD15 and LAA in the non-dependent lobes
(pZ 0.03, pZ 0.04 and pZ 0.02, respectively), whereas
age and BMI were not significant predictors of these signs
of air trapping.Table 2 Demographics, lung function, and CT scan data
Femal
Age (years) 34
Body mass index (kg/m2) 24.5
Alveolar eNO (ppb) 14.5
Bronchial eNO (nL/s) 3.9
PC20MCh (mg/mL) 0.31
PC20 AMP (mg/mL) 1.34
Closing volume (mL) 155
dN2 (%N2/mL) 1.3
FEV1 (% pred) 84
FVC (% pred) 101
SVC (% pred) 103
FEF25e75% (% pred) 63
FEF50% (% pred) 65
Lung volume on expiratory CT scan (mL) 2224
Mean lung density on expiratory CT scan (HU) 694
15th percentile density on expiratory CT scan (HU) 870
% LAA on expiratory CT scan (%) 3.9
Values are medians (ranges). Gender differences were tested by Man
eNO: exhaled nitric oxide, MCh: Methacholine, AMP: adenosine-50-mon
LAA: low attenuation areas (950 HU).Discussion
This study demonstrates that, even in a small group of
patients with asthma, differences exist between males and
females with respect to small airway involvement. Males
have more Methacholine-induced air trapping than fe-
males, especially in the non-dependent lung lobes, whereas
females have significantly higher bronchial fractions of
exhaled NO than males.
Small airway involvement in asthma is prominent in
severe persistent asthma,19,27,28 and has also been demon-
strated to play a role in mild-to-moderate asthma,29,30 The
extent of small airway involvement in asthma has been es-
timated to be more pronounced when the disease is more
severe.19 Whether other factors, such as age, body mass in-
dex or gender affect the extent of small airway involve-
ment has up to now not been investigated. This study for
the first time demonstrates that gender may indeed play
a significant role in the extent of small airway involvement
in asthma. MCh-induced air trapping as a result of small air-
way pathology was larger in males than in females. More-
over, males demonstrated a larger degree of impaired
small airway patency, as reflected by air trapping, closing
volume, and FEF25e75%. This suggests that small airway di-
mensions play a more important role in the clinical expres-
sion of asthma in males than in females. Notwithstanding
this, females in this study had higher fractions of bronchial
eNO, which reflects inflammation in the large airways, but
to some extent also that in small airways. Small airway in-
volvement may therefore not only differ in extent but also
in expression between both genders, i.e. in males airway
dimensions and in females airway inflammation may be
the key feature of small airway involvement in asthma.
Gender differences in the extent of air trapping quan-
tified with CT scans have been described previously by
Hashimoto et al. In a group of 20 healthy subjects, aires (nZ 9) Males (nZ 7) p-Value
(19e56) 44 (20e53) 0.25
(19.3e27.0) 25.5 (21.9e30.1) 0.09
(8.3e67.3) 16.9 (6.9e31.8) 0.96
(1.6e7.4) 2.0 (1.0e3.7) 0.04
(0.09e1.33) 0.46 (0.08e4.22) 0.30
(0.16e36.16) 5.84 (0.24e21.33) 0.68
(70e260) 443 (60e820) 0.11
(0.6e2.3) 2.2 (1.3e3.6) 0.07
(62e120) 97 (69e111) 0.35
(84e144) 115 (95e132) 0.30
(82e845) 116 (94e129) 0.47
(29e87) 51 (39e79) 0.61
(32e102) 49 (42e85) 0.61
(2061e2833) 3325 (2967e3423) 0.02
(731 to 606) 716 (713 to 667) 0.84
(895 to 801) 889 (907 to 861) 0.25
(1.8e6.4) 5.9 (4.5e8.1) 0.21
neWhitney U test.
ophosphate, dN2: slope of nitrogen washout, HU: Hounsfield Units,
Figure 1 Bronchial eNO in males and females; eNO: exhaled
nitric oxide.
1268 J. Cohen et al.trapping was detectable in six women and five men. The ex-
tent of air trapping was significantly greater in men than in
women.31 In line with this, Ooi et al. demonstrated that
there were also significant differences between men and
women with bronchiectasis, females showing less small air-
way abnormalities than males.32 In our study group consist-
ing of 16 patients with asthma, the extent of air trapping
was also greater in men than in women. In addition, we
demonstrated a regional difference in air trapping, since
men demonstrated more air trapping in the non-dependent
lung lobes than women. This may hypothetically result from
a difference in Methacholine deposition due to differences
in bronchial tree anatomy, or due to different tidal breath-
ing patterns, or even to a difference in small airway col-
lapsibility. Martinez and colleagues demonstrated thatp=0.113
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Figure 2 a) Closing volume b) dN2 c) FEF25-75% and d) FEF50% in m
forced expiratory flow at 25-75% of forced vital capacity, FEF50%: ffemales with severe emphysema have thicker small airways
relative to luminal perimeters than males.33 If this could be
extrapolated to asthma, small airways in females may be
less responsive to bronchoconstrictive agents due to their
thicker and more rigid structure. This could explain why fe-
males demonstrate less air trapping than males, despite
their increased small airway inflammation, as was demon-
strated by a higher bronchial eNO.
The MCh-induced increase in volume and decrease in
both MLD and PD15 were larger in males than in females,
but did not differ significantly. This is likely due to the small
sample size. Post-hoc power calculation showed that
a sample size of 29 patients would be needed to demon-
strate gender differences in MCh-induced changes in
volume, MLD, and PD15. In addition, the lack of statistical
power may also explain the absence of gender differences
in other small airway parameters, such as closing volume
and dN2 with SBN2 test, and FEF25e75% and FEF50%. These pa-
rameters were all more attenuated in males than in fe-
males, indicating that male asthmatics in this study had
more small airway geometric abnormalities than their fe-
male counterparts. The described gender differences may
be larger than portrayed in this study, especially since
they can already be observed in a small study group.
It is important to also appreciate the limitations of this
study. It has been described that in utero smoke exposure,
exposure to smoke or air pollution in childhood and a posi-
tive family history of pulmonary diseases may influence air-
way and lung development, which may lead to small airway
abnormalities and asthma.12 These characteristics were not
available in our study subjects and therefore it is unknown
to what extent these factors may have contributed to the
observed gender differences. A second limitation is thatb
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ales and females dN2: slope of the alveolar plateau, FEF25-75%:
orced expiratory flow at 50% of forced vital capacity.
Table 3 Methacholine-induced air trapping on CT
Females Males p-Value
Volume change, total lung (%),
non-dependent lobes (%),
dependent lobes (%)
14 (2e39) 25 (9e35) 0.14
12 (10e35) 31 (1e40) 0.09
16 (7e48) 25 (14e32) 0.09
MLD change, total lung (HU),
non-dependent lobes (HU),
dependent lobes (HU)
45 (13 to 128) 80 (39 to 157) 0.06
25 (52 to 143) 120 (15 to 193) 0.03
133 (63 to 327) 90 (54 to 195) 0.25
PD15 change, total lung (HU),
non-dependent lobes (HU),
dependent lobes (HU)
31 (4 to 89) 44 (15 to 101) 0.14
26 (64 to 116) 77 (5 to 142) 0.04
45 (22 to 117) 50 (30 to 143) 0.68
LAA change, total lung (%),
non-dependent lobes (%),
dependent lobes (%)
2 (1e7) 6 (1e9) 0.02
2 (4e7) 11 (0e16) 0.01
2 (1e8) 5 (2e7) 0.06
Values are medians (ranges). Gender differences were tested by ManneWhitney U test. MLD: mean lung density, HU: Hounsfield Units,
PD15: 15th percentile density, LAA: low attenuation areas (HU950 HU).
Gender and small airways in asthma 1269there is no pathological evidence available to support that
the extent of small airway involvement in asthma is differ-
ent between the two sexes. Nevertheless, our results war-
rant further investigations to assess in a larger group
whether gender differences in small airways are of clinical
relevance in the work-up of asthma.
Both airway geometry and airway inflammation contrib-
ute to the presence and severity of airway hyperrespon-
siveness. It is well known that anti-inflammatory treatment
can improve hyperresponsiveness immediately34 and that
persistent treatment provides further ongoing improve-
ment in hyperresponsiveness.35 Sont et al. also showedFigure 3 Methacholine-induced air trapping assessed with CT in m
lung volume (%) in the dependent and non-dependent lung lobes.
lung, (c) non-dependent lung lobes and (d) dependent lung lo
(density  950 HU), MCh: Methacholine.that this long-term improvement is associated with im-
provement of airway remodelling.36 Based on our findings,
one could argue that anti-inflammatory therapy would ben-
efit males in particular when affecting airway geometry and
females when improving acute inflammation in the small
airways. This might explain why Convery found that short-
term treatment with large-particle ICS had less beneficial
effects in females,37 who according to our observations
have more small airway inflammation, thus in a location
less reached with large-particle size steroids. Dijkstra
et al. showed that treatment with large-particle ICS in
adult males was associated with a reduction in FEV1 declineales and females e (a) MCh-induced change in end-expiratory
(b) MCh-induced changes in MLD (HU) and LAA (%) in the total
bes. MLD: Mean lung density, LAA: low attenuation areas
1270 J. Cohen et al.over a 23-year follow-up in males only.38 This observation
might reflect the effects of long-term treatment with ICS
on airway geometry as a result of improvement in small air-
way remodelling over this time period. This would then
have a larger effect in male asthmatics who have more ex-
tensive changes in airway geometry compared to female
asthmatics. This clearly is speculative and needs further
study, yet it needs to be further explored since small-parti-
cle size ICS are now available which have been demon-
strated to reach the small airways and to exert anti-
inflammatory effects on specifically small airways.29,30,39,40
Small-particle ICS could modify the severity, control and
the progression of asthma differently in females and males.
In summary, in a small group of patients with mild-to-
moderate asthma, there are significant differences be-
tween males and females with respect to eNO and small
airway patency in response to Methacholine, suggesting
that small airways are affected differently in males and
females with asthma. Possibly, small airway involvement in
asthma in females is expressed by more small airway
inflammation, whereas in males small airway collapsibility
may be the key feature of small airway involvement. These
results warrant further investigations into the role of small
airway involvement in asthma and particularly in severe
asthma, which predominantly affects females.
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